Samuel C. Blackman - Aug 15, 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Signature
/s/ Charles N. York II, Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Aug 15, 2022
Transactions value $
-$22,876
Form type
4
Date filed
8/17/2022, 07:25 PM
Previous filing
Aug 3, 2022
Next filing
Sep 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Options Exercise $0 +3.56K +0.27% $0.00 1.3M Aug 15, 2022 Direct
transaction DAWN Common Stock Sale -$22.9K -941 -0.07% $24.31 1.3M Aug 16, 2022 Direct F1
holding DAWN Common Stock 1M Aug 15, 2022 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Restricted Stock Units Options Exercise $0 -3.56K -18.74% $0.00 15.4K Aug 15, 2022 Common Stock 3.56K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").
F2 The Reporting Person is the sole manager, and has shared voting and dispositive power with his wife as members. The Reporting Person continues to report beneficial ownership of all of the Issuer's Common Stock held by the 2021 Blackman Family LLC but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest therein.
F3 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F4 The RSUs will vest as to 1/12 of the total award in quarterly installments on February 15th, May 15th, August 15th, and November 15th, subject to the Reporting Person's continued service to the Issuer on each vesting date.